Updates are available Correction dated 2023-08-01
Click to view Correction: https://doi.org/10.1038/s41433-023-02662-1
-
Authors
Loewenstein, Anat https://orcid.org/0000-0002-7706-1165
Berger, Alan
Daly, Avril
Creuzot-Garcher, Catherine
Gale, Richard
Ricci, Federico
Zarranz-Ventura, Javier https://orcid.org/0000-0003-2338-8143
Guymer, Robyn https://orcid.org/0000-0002-9441-4356
- License Information
-
More Information
Article History
Received: 7 February 2023
Revised: 5 April 2023
Accepted: 11 April 2023
First Online: 6 June 2023
Change Date: 1 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-023-02662-1
Competing interests
: AL has consulted for Roche, Notal Vision, Bayer, Novartis, and Abbvie. RGu consults with Roche, Genentech, Apellis, Bayer, Novartis, and Janssen Research & Development. RGa has received institutional research grants funded by Bayer, Novartis, and Roche and has consulted for Apellis, Allergan, Biogen, Bayer, Novartis, Roche. AD does not have any direct competing interests to disclose; however, Retina International (where Avril serves as CEO) receives unrestricted educational grants from, F. Hoffman LaRoche, Novartis, Apellis, and Janssen. FR and JZ-V are members of the <i>Eye</i> editorial board. AB and CC-G declare no competing interests.
